In early stage non-small cell lung cancer (NSCLC) definitive radiation therapy is an appropriate alternative to surgery. Recent studies show, that in such patients hypofractionation schedules (for example 3 times 18 Gy or 5 times 12 Gy), can be safely applied, without causing severe toxicities and achieving high local control rates of up to 90% and more. In the last couple of years a lot of knowledge about the cancer biology, technical aspects, clinical outcomes and toxicities has been accumulated from different clinical trials. The purpose of this review is to summarize recent outcomes and developments in stereotactic radiation therapy for patients with early stage NSCLC.

Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? / Simeonova, A. O.; Fleckenstein, K.; Wertz, H.; Frauenfeld, A.; Boda-Heggemann, J.; Lohr, F.; Wenz, F.. - In: TRANSLATIONAL LUNG CANCER RESEARCH. - ISSN 2218-6751. - 1:1(2012), pp. 45-53. [10.3978/j.issn.2218-6751.10.01]

Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

Lohr F.;
2012

Abstract

In early stage non-small cell lung cancer (NSCLC) definitive radiation therapy is an appropriate alternative to surgery. Recent studies show, that in such patients hypofractionation schedules (for example 3 times 18 Gy or 5 times 12 Gy), can be safely applied, without causing severe toxicities and achieving high local control rates of up to 90% and more. In the last couple of years a lot of knowledge about the cancer biology, technical aspects, clinical outcomes and toxicities has been accumulated from different clinical trials. The purpose of this review is to summarize recent outcomes and developments in stereotactic radiation therapy for patients with early stage NSCLC.
1
1
45
53
Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? / Simeonova, A. O.; Fleckenstein, K.; Wertz, H.; Frauenfeld, A.; Boda-Heggemann, J.; Lohr, F.; Wenz, F.. - In: TRANSLATIONAL LUNG CANCER RESEARCH. - ISSN 2218-6751. - 1:1(2012), pp. 45-53. [10.3978/j.issn.2218-6751.10.01]
Simeonova, A. O.; Fleckenstein, K.; Wertz, H.; Frauenfeld, A.; Boda-Heggemann, J.; Lohr, F.; Wenz, F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1250199
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact